Slide info
| Conference | ASCO |
| Date | Jun 19, 2019 |
| Slide type | Poster |
| Source | Full poster |
Key insights
ABSTRACT 4123, Board 228 Neoadjuvant FOLFIRINOX versus adjuvant gemcitabine in pancreatic cancer
► Background: In the metastatic or adjuvant setting for pancreatic cancer, the combination chemotherapy of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) resulted in longer overall survival (OS) compared to gemcitabine therapy. This institutional study was conducted to compare the efficacy of neoadjuvant mFOLFIRINOX to adjuvant gemcitabine for pancreatic cancer patients who completed resection
► Presenter: A Wolfe KEY INS IGHTS
► Borderline resectable and unresectable pancreatic cancer patients who received neoadjuvant mFOLFIRINOX and completed resection had longer OS, DFS, and more favorable pathological indicators compared to those patients who had upfront surgery and adjuvant gemcitabine
►On multivariate analysis, neoadjuvant FOLFIRINOX was a significant predictors of OS and time to progression
► Randomized clinical trials comparing neoadjuvant vs adjuvant FOLFIRINOX are needed to validate these findings